In the short term getting RC220 into the first patient. Mid term showing bisantrene is a cardioprotective anticancer drug in patients. While we have so much preclinical and historical data that supports this hypothesis, until it shown in the clinic it remains speculative.
Long term it is being able to change how chemotherapy is used. There is so much that could be done that is not done to help patients. Bisantrene could be the catalyst for major change that could help millions of people.
Industry news, page-2301
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.55 | $189.9K | 121.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1316 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 34961 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |